Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Completed · Phase 1

Conditions studied: Prostate Cancer

In brief

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of muJ591 monoclonal antibody in treating patients who have metastatic prostate cancer that has not responded to hormone therapy.

Key facts

Study ID

NCT00003391

Run by

Weill Medical College of Cornell University

People needed

30

Starts

1998-06-01

Last updated by the study team

2009-10-12

Who can join

Age: 21 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• New York Presbyterian Hospital - Cornell Campus — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.